Literature DB >> 21355857

The prevalence and demographic distribution of treated epilepsy: a community-based study in Tasmania, Australia.

W J D'Souza1, S J Quinn, J L Fryer, B V Taylor, D M Ficker, T J O'Brien, N Pearce, M J Cook.   

Abstract

OBJECTIVES: To estimate the prevalence and demographic distribution of treated epilepsy in a community-based population. MATERIALS &
METHODS: We surveyed all residents in Tasmania, Australia, who were supplied at least one antiepileptic drug prescription between July 1, 2001 and June 30, 2002, recorded on the national prescription database. We adjusted for the effect of disease-related non-response bias by imputation methods.
RESULTS: After three mail contacts, 54.0% (4072/7541) responded, with 1774 (43.6%) indicating treatment for epilepsy, representing 86.0% of the estimated total possible cases in Tasmania. The adjusted treated epilepsy prevalence was 4.36 per 1000 (95% CI 4.34, 4.39); lower in women (prevalence ratio 0.92 (95% CI 0.84, 1.00)); greater with increasing age (P < 0.001); similar in the three main geographic regions; and similar with socioeconomic status of postcode of residence.
CONCLUSIONS: Although our estimates are likely to be affected by access to health services, overall treated epilepsy prevalence of 4.4 per 1000 is similar to previous studies. Our finding of high elderly prevalence has been reported in a few recent studies in developed countries and has important clinical and public health implications in populations with similar aging demographics.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21355857     DOI: 10.1111/j.1600-0404.2011.01499.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

Review 1.  The long-term safety of antiepileptic drugs.

Authors:  Athanasios Gaitatzis; Josemir W Sander
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

2.  Psychiatric Comorbidity, Social Aspects and Quality of Life in a Population-Based Cohort of Expecting Fathers with Epilepsy.

Authors:  Simone Frizell Reiter; Gyri Veiby; Marte Helene Bjørk; Bernt A Engelsen; Anne-Kjersti Daltveit; Nils Erik Gilhus
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

3.  Protocol for a single patient therapy plan: A randomised, double-blind, placebo-controlled N-of-1 trial to assess the efficacy of cannabidiol in patients with intractable epilepsy.

Authors:  Katherine S Ong; John B Carlin; Michael Fahey; Jeremy L Freeman; Ingrid E Scheffer; Lynn Gillam; Monique Anderson; Md Hamidul Huque; Donna Legge; Nicole Dirnbauer; Brian Lilley; Simon Slota-Kan; Noel Cranswick
Journal:  J Paediatr Child Health       Date:  2020-09-23       Impact factor: 1.954

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.